Novo Nordisk submits etavopivat to FDA and EMA for sickle cell disease following Phase 3 HIBISCUS results showing reduced VOCs and improved haemoglobin response.
Written By: Malavatu Satvika, PharmD
Reviewed By: Pharmacally Editorial Team
On November 12, 2026, Novo Nordisk announced the submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) and a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for etavopivat, an investigational once-daily oral therapy for adolescents and adults aged 12 years and older with sickle cell disease (SCD). The applications are supported by Phase 3 HIBISCUS results demonstrating a 27% reduction in annualised vaso-occlusive crisis (VOC) rates and improvements in haemoglobin response compared with placebo.
If approved, etavopivat could introduce a disease-modifying approach targeting red-cell metabolism in SCD, a progressive inherited blood disorder characterised by abnormal haemoglobin, recurrent painful crises and chronic haemolytic anaemia. The disease can also cause progressive organ damage and substantially reduce life expectancy.
From Red-Cell Metabolism to Potential Disease Modification
Etavopivat is an investigational, once-daily oral, selective activator of the red blood cell isozyme pyruvate kinase (PKR), an enzyme involved in glycolysis. PKR activation is intended to reduce 2,3-diphosphoglycerate (2,3-DPG) levels while increasing adenosine triphosphate (ATP) production.
Lower 2,3-DPG increases haemoglobin’s affinity for oxygen, potentially reducing sickle haemoglobin (HbS) polymerisation and subsequent red-cell sickling. Increased ATP may help maintain red-cell membrane integrity and deformability, potentially improving cell survival.
Unlike treatments primarily directed at managing pain or inflammation, etavopivat targets the metabolic processes contributing to red-cell dysfunction. Whether these effects translate into sustained reductions in VOCs, improved anaemia and fewer long-term complications remains an important question for clinical and regulatory assessment.
HIBISCUS: Clinical Evidence Supporting the Submissions
The regulatory applications are supported by HIBISCUS (NCT04624659), a pivotal Phase 3, randomised, double-blind, 52-week trial evaluating once-daily etavopivat against placebo in 385 participants aged 12 years and older. Participants could continue standard-of-care treatment throughout the study.
Eligible participants had sickle cell disease and a history of VOCs. Following a 12-week Phase 2 interim assessment, the Phase 3 dose was selected and participants entered the main study phase. The trial assessed two co-primary endpoints: annualised VOC rate through Week 52 and the proportion of participants achieving a haemoglobin increase greater than 1 g/dL at Week 24.
Both Co-Primary Endpoints Met in HIBISCUS
In April 2026, Novo Nordisk reported that etavopivat met both co-primary endpoints.
The treatment reduced the annualised VOC rate by 27% compared with placebo. It also prolonged the median time to the first VOC to 38.4 weeks, compared with 20.9 weeks for placebo, representing an approximately four-month delay.
The haemoglobin findings provided a second efficacy signal. At Week 24, 48.7% of participants receiving etavopivat achieved an increase greater than 1 g/dL, compared with 7.2% in the placebo group. The adjusted rate difference was 41.2%.
An exploratory analysis also showed a significant reduction in the risk of blood transfusion with etavopivat. Together, these findings indicate activity across vaso-occlusive events and haemolytic anaemia, two important aspects of SCD.
However, the topline announcement does not provide the complete statistical analyses, absolute VOC rates, detailed subgroup findings or comprehensive transfusion data. Full clinical reporting will be important to evaluate the magnitude and consistency of treatment effects.
Safety, Regulatory Progress and Further Development
Novo Nordisk described etavopivat as well tolerated, with a topline safety profile consistent with previous trials. Nevertheless, detailed adverse-event frequencies, serious adverse events and treatment discontinuations are needed to establish its complete benefit-risk profile.
Etavopivat has received FDA Fast Track, Rare Pediatric Disease and Orphan Drug designations. The European Commission has also granted Orphan Drug designation following a positive opinion from EMA’s Committee for Orphan Medicinal Products. These designations support development and regulatory review but do not guarantee approval.
The broader clinical programme includes HIBISCUS 2 (NCT06612268), a 52-week Phase 3b study comparing etavopivat with standard of care/placebo in 408 participants aged 12 years and older. FLORAL (NCT06609226), an open-label extension study, is intended to provide longer-term safety information.
Clinical Interpretation
The FDA and EMA submissions mark an important regulatory milestone for an oral therapy targeting red-cell metabolism in SCD. HIBISCUS demonstrated improvements across both co-primary endpoints, with additional exploratory evidence suggesting a reduced need for blood transfusions.
The haemoglobin response strengthens the clinical evidence beyond VOC reduction alone, suggesting that etavopivat may provide benefits across two important manifestations of SCD. However, HIBISCUS was not designed to establish whether these improvements translate into prevention of progressive organ damage or improved survival. Longer-term clinical evidence will be needed to determine whether the observed benefits result in durable disease modification. The trial’s enrolment criteria, including participants’ previous VOC history, also define the population to which the results can most directly be applied.
The regulatory reviews will therefore be important in determining whether the observed benefits, alongside the complete safety profile, support approval for adolescents and adults with SCD. Until those reviews are completed, etavopivat remains investigational.
Reference
Novo submits etavopivat, an investigational once-daily therapy for adolescents and adults living with sickle cell disease, to the FDA and EMA for approval, Novo Nordisk, 13 November 2026
A Study of Etavopivat in Adults and Adolescents with Sickle Cell Disease (HIBISCUS) (HIBISCUS), ClinicalTrials.gov ID NCT04624659
About the Writer
Malavatu Satvika (Linkedin) is a Pharm.D professional and aspiring healthcare medical writer with clinical exposure and research experience. Her interests include medical writing, drug safety, pharmaceutical research, and evidence-based healthcare communication. She has contributed to two research publications in pharmaceutical journals and has gained practical experience in prescription review, patient counselling, medication review, adverse drug reaction monitoring, drug information services, literature review, and clinical documentation through regular hospital training.
She has completed certifications in clinical research, ICH-GCP E6(R3), data management for clinical research, and congenital hypothyroidism. With a strong foundation in pharmacy, clinical practice, and scientific research, she aims to translate complex medical and pharmaceutical information into accurate, clear, and evidence-based healthcare content. She is also preparing to pursue a PhD and further develop her expertise in medical writing and pharmaceutical research.